Skip to Content

TCR² Therapeutics Inc.

Merger

  • Date:
  • 3/6/2023
  • Company Name:
  • TCR² Therapeutics Inc.
  • Stock Symbol:
  • TCRR
  • Company Name - Buyer:
  • Adaptimmune Therapeutics plc
  • Stock Symbol - Buyer:
  • ADAP
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 3/6/2023

Case Finder

Locate any case using the tools below.

Contact Instructions
NEW YORK, March 6, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of TCR² Therapeutics Inc. (NASDAQ: TCRR) (“TCR²”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Adaptimmune Therapeutics plc (NASDAQ: ADAP) (“Adaptimmune”).

On March 6, 2023, TCR² announced that it had entered into an agreement to be acquired by Adaptimmune in an all-stock deal. Pursuant to the merger agreement, TCR2 stockholders will receive 1.5117 Adaptimmune ADS for each TCR2 share. Following the closing of the transaction, Adaptimmune shareholders will own approximately 75% of the combined company and TCR2 stockholders will own approximately 25% of the combined company. The deal is expected to close in second quarter of 2023.

Bragar Eagel & Squire is concerned that TCR²’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for TCR²’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in TCR² Therapeutics Inc.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: